Kezar Life Sciences, Inc. DEF 14A SEC Filings

Filed On	Filing
25 Apr 2025	Proxy statement: annual meeting on June 17, 2025 CEO pay $927K, down 64% · say-on-pay vote
26 Apr 2024	DEF 14A CEO pay $2.6M, up 5.3%
27 Apr 2023	DEF 14A
26 Apr 2022	DEF 14A
29 Apr 2021	DEF 14A
29 Apr 2020	DEF 14A
30 Apr 2019	DEF 14A

Comments